Published in:
Open Access
30-11-2023 | Acute Coronary Syndrome | Original article
Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol
Authors:
Alessandro Maloberti, Rita Cristina Myriam Intravaia, Costantino Mancusi, Arturo Cesaro, Enrica Golia, Fucile Ilaria, Silvio Coletta, Piera Merlini, Benedetta De Chiara, Davide Bernasconi, Michela Algeri, Paolo Ossola, Claudio Ciampi, Alfonso Riccio, Chiara Tognola, Maddalena Ardissino, Elvira Inglese, Francesco Scaglione, Paolo Calabrò, Nicola De Luca, Cristina Giannattasio
Published in:
High Blood Pressure & Cardiovascular Prevention
|
Issue 6/2023
Login to get access
Abstract
Introduction
Despite significant improvement in secondary CardioVascular (CV) preventive strategies, some acute and chronic coronary syndrome (ACS and CCS) patients will suffer recurrent events (also called “extreme CV risk”). Recently new biochemical markers, such as uric acid (UA), lipoprotein A [Lp(a)] and several markers of inflammation, have been described to be associated with CV events recurrence. The SEcondary preVention and Extreme cardiovascular Risk Evaluation (SEVERE-1) study will accurately characterize extreme CV risk patients enrolled in cardiac rehabilitation (CR) programs. Aim. Our aims will be to describe the prevalence of extreme CV risk and its association with newly described biochemical CV risk factors.
Aim
Our aims will be to describe the prevalence of extreme CV risk and its association with newly described biochemical CV risk factors.
Methods
We will prospectively enrol 730 ACS/CCS patients at the beginning of a CR program. Extreme CV risk will be retrospectively defined as the presence of a previous (within 2 years) CV events in the patients’ clinical history. UA, Lp(a) and inflammatory markers (interleukin-6 and -18, tumor necrosis factor alpha, C-reactive protein, calprotectin and osteoprotegerin) will be assessed in ACS/CCS patients with extreme CV risk and compared with those without extreme CV risk but also with two control groups: 1180 hypertensives and 765 healthy subjects. The association between these biomarkers and extreme CV risk will be assessed with a multivariable model and two scoring systems will be created for an accurate identification of extreme CV risk patients. The first one will use only clinical variables while the second one will introduce the biochemical markers. Finally, by exome sequencing we will both evaluate polygenic risk score ability to predict recurrent events and perform mendellian randomization analysis on CV biomarkers.
Conclusions
Our study proposal was granted by the European Union PNRR M6/C2 call. With this study we will give definitive data on extreme CV risk prevalence rising attention on this condition and leading cardiologist to do a better diagnosis and to carry out a more intensive treatment optimization that will finally leads to a reduction of future ACS recurrence. This will be even more important for cardiologists working in CR that is a very important place for CV risk definition and therapies refinement.